NEW YORK, NY / ACCESSWIRE / November 28, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on Immunomedics, Inc. (NASDAQ: IMMU), a clinical-stage pharmaceutical company. The company's principal area of investigation is monoclonal antibody-based products capable of treating cancer, autoimmune disorders, and other diseases.
Immunomedics' portfolio of products consists of antibody-drug conjugated (ADCs) that are designed to deliver a specific payload of a chemotherapeutic directly to the tumor while reducing overall toxic effects to the patient. The company's most advanced product candidate is IMMU-132 (sacituzumab govitecan), an ADC that has received breakthrough therapy designation from the FDA for the treatment of triple-negative breast cancer.
The company will be making presentations in December for IMMU-132.
Review the entire IMMU pipeline, analysts target price, and company outlook: READ MORE.
Copy and paste into your browser may be required to view the report - http://tradersnewssource.com/immunomedics/.
Triple-negative breast cancer represents approximately 15 percent of all breast cancer diagnosed, and there is currently no standard therapy in adjuvant or metastatic settings. The median survival rate is approximately 12 months, and the progression-free survival rate (PFS) is between 1.7 and 3.7 months.
In the course of its research activities, the company has accumulated a large portfolio of patents related to its product candidates as well as other technologies for which product candidates have not yet been identified. As of August 1, 2016, Immunomedics held nearly 300 patents in the United States and more than 400 foreign patents. The vast majority of the company's patents expire between 2023 and 2033.
Get a financial review, analysts opinion, along with the company's FDA drug status here: READ MORE.
Copy and paste into your browser may be required to view the report - http://tradersnewssource.com/immunomedics/.
Disclosure
Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
TNS has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. Ivan Nielson, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
CONTACT:
SOURCE: Traders News Source
